Pub Date : 2025-01-01DOI: 10.1016/j.retram.2025.103502
Kaiyuan Song , Yongbin Wu , Sipin Tan
Recent studies prove that the three well-established cell death pathways—pyroptosis, apoptosis, and necroptosis—are not isolated but rather engage in extensive crosstalk. PANoptosis, a newly identified pathway of inflammatory regulated cell death (RCD), integrates characteristics of apoptosis, pyroptosis, and necroptosis. Caspases are a family of conserved cysteine proteases that play critical roles in pyroptosis, apoptosis, and necroptosis. Similarly, caspases also play a role in PANoptosis. In this paper, we review the molecular mechanisms of these three RCDs and the crosstalk between them. We also delineate the discovery of PANoptosis and its association with disease. Furthermore, we discuss the caspase function in PANoptosis, mainly focusing on caspase-6 and caspase-8 molecules. This review describes the key molecules, especially caspases, in the context of PANoptosis research, aiming to provide a foundation for targeted interventions in PANoptosis-associated diseases.
{"title":"Caspases in PANoptosis","authors":"Kaiyuan Song , Yongbin Wu , Sipin Tan","doi":"10.1016/j.retram.2025.103502","DOIUrl":"10.1016/j.retram.2025.103502","url":null,"abstract":"<div><div>Recent studies prove that the three well-established cell death pathways—pyroptosis, apoptosis, and necroptosis—are not isolated but rather engage in extensive crosstalk. PANoptosis, a newly identified pathway of inflammatory regulated cell death (RCD), integrates characteristics of apoptosis, pyroptosis, and necroptosis. Caspases are a family of conserved cysteine proteases that play critical roles in pyroptosis, apoptosis, and necroptosis. Similarly, caspases also play a role in PANoptosis. In this paper, we review the molecular mechanisms of these three RCDs and the crosstalk between them. We also delineate the discovery of PANoptosis and its association with disease. Furthermore, we discuss the caspase function in PANoptosis, mainly focusing on caspase-6 and caspase-8 molecules. This review describes the key molecules, especially caspases, in the context of PANoptosis research, aiming to provide a foundation for targeted interventions in PANoptosis-associated diseases.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103502"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2024.103487
Thibaud Loupret, Laurie De Coster, Camille Lemaçon, Emma Gadon, Philippe Bertin, Pascale Vergne-Salle
{"title":"Non-hematological triggers of VEXAS syndrome: A case report and literature review","authors":"Thibaud Loupret, Laurie De Coster, Camille Lemaçon, Emma Gadon, Philippe Bertin, Pascale Vergne-Salle","doi":"10.1016/j.retram.2024.103487","DOIUrl":"10.1016/j.retram.2024.103487","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103487"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2025.103501
Shiyuan Zhou , Chao Ma , Danping Zhou , Qian Zhu , Wenjuan Zhu , Jing Li , Depei Wu , Xiao Ma , Xiaojin Wu
Introduction
Research on anti-lymphocyte globulins other than rabbit anti-thymocyte globulin (r-ATG) in prevention of graft-versus-host-disease (GVHD) following HLA-matched siblings hematopoietic stem cell transplantation (MSD-HSCT) is limited. The objective of this study is to investigate the distinct impacts of porcine anti-human T lymphocyte immunoglobulin (p-ATG) and r-ATG on outcomes of MSD-HSCT in patients with hematologic malignancies.
Patients and methods
This retrospective analysis enrolled 373 consecutive patients who underwent MSD-HSCT from January 2019 to October 2023. 135 patients received r-ATG (5mg/kg) and 51 received p-ATG (30mg/kg) for GVHD prophylaxis. 187 did not receive r-ATG or p-ATG.
Results
Despite early deaths, no engraftment failure occurred. In the r-ATG group, neutrophil engraftment was observed earlier, while platelet engraftment was delayed compared to other groups. Both r-ATG and p-ATG group showed protective effect on chronic graft-versus-host disease (cGVHD) (13.9 % and 29.6 % respectively vs. 43.0 % of control group at 2 years post HSCT), whereas only the r-ATG group displayed a decreased acute GVHD (aGVHD) rate (24.9 % vs. 39.8 % of control group at day 100 post HSCT). GVHD-free and relapse-free survival (GRFS) were found superior in both r-ATG and p-ATG groups (63.4 % and 56.8 % respectively vs. 37.0 % of control group at 2 years post HSCT). R-ATG was identified as an independent protective factor for aGVHD, cGVHD and GRFS in multivariate analysis.
Conclusions
Our study further confirmed the role of ATG in MSD-HSCT for improving the outcomes. No evidence supported substituting r-ATG with p-ATG in achieving these effects in the study.
{"title":"A comparison of porcine anti-human T lymphocyte immunoglobulin, rabbit-ATG for GVHD prophylaxis and without ATG in matched sibling donor transplantation","authors":"Shiyuan Zhou , Chao Ma , Danping Zhou , Qian Zhu , Wenjuan Zhu , Jing Li , Depei Wu , Xiao Ma , Xiaojin Wu","doi":"10.1016/j.retram.2025.103501","DOIUrl":"10.1016/j.retram.2025.103501","url":null,"abstract":"<div><h3>Introduction</h3><div>Research on anti-lymphocyte globulins other than rabbit anti-thymocyte globulin (r-ATG) in prevention of graft-versus-host-disease (GVHD) following HLA-matched siblings hematopoietic stem cell transplantation (MSD-HSCT) is limited. The objective of this study is to investigate the distinct impacts of porcine anti-human T lymphocyte immunoglobulin (p-ATG) and r-ATG on outcomes of MSD-HSCT in patients with hematologic malignancies.</div></div><div><h3>Patients and methods</h3><div>This retrospective analysis enrolled 373 consecutive patients who underwent MSD-HSCT from January 2019 to October 2023. 135 patients received r-ATG (5mg/kg) and 51 received p-ATG (30mg/kg) for GVHD prophylaxis. 187 did not receive r-ATG or p-ATG.</div></div><div><h3>Results</h3><div>Despite early deaths, no engraftment failure occurred. In the r-ATG group, neutrophil engraftment was observed earlier, while platelet engraftment was delayed compared to other groups. Both r-ATG and p-ATG group showed protective effect on chronic graft-versus-host disease (cGVHD) (13.9 % and 29.6 % respectively vs. 43.0 % of control group at 2 years post HSCT), whereas only the r-ATG group displayed a decreased acute GVHD (aGVHD) rate (24.9 % vs. 39.8 % of control group at day 100 post HSCT). GVHD-free and relapse-free survival (GRFS) were found superior in both r-ATG and p-ATG groups (63.4 % and 56.8 % respectively vs. 37.0 % of control group at 2 years post HSCT). R-ATG was identified as an independent protective factor for aGVHD, cGVHD and GRFS in multivariate analysis.</div></div><div><h3>Conclusions</h3><div>Our study further confirmed the role of ATG in MSD-HSCT for improving the outcomes. No evidence supported substituting r-ATG with p-ATG in achieving these effects in the study.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103501"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Non-valvular atrial fibrillation following COVID-19 in a young female with FGFR3 mutation: A challenging concern","authors":"Sawsan Ismail , Firas Hamed , Tamim Alsuliman , Kanaan Al-Tameemi","doi":"10.1016/j.retram.2025.103497","DOIUrl":"10.1016/j.retram.2025.103497","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103497"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2024.103489
Moloud Ahmadi, Nicholas Putnam, Max Dotson, Danny Hayoun, Jasmine Padilla, Nujhat Fatima, Prajakta Bhanap, Gertrude Nonterah, Xavier de Mollerat du Jeu, Yongchang Ji
The traditional method of CAR T cell production involves lengthy ex-vivo culture times which can result in the reduction of crucial naïve T cell subsets. Moreover, traditional CAR T cell therapy manufacturing processes can prolong time-to-patient, potentially delaying patient treatment, and contribute to disease progression. In this study, we describe an innovative and semi-automated 24-hour CAR T manufacturing process that yields a higher percentage of naïve/stem-cell like T cells which showed high cytotoxic activity and cytokine release in vitro. The data supports the feasibility of implementing this streamlined manufacturing process in clinics. This approach also has the potential to enhance CAR T therapy efficacy and improve patient access to therapy.
{"title":"Accelerating CAR T cell manufacturing with an automated next-day process","authors":"Moloud Ahmadi, Nicholas Putnam, Max Dotson, Danny Hayoun, Jasmine Padilla, Nujhat Fatima, Prajakta Bhanap, Gertrude Nonterah, Xavier de Mollerat du Jeu, Yongchang Ji","doi":"10.1016/j.retram.2024.103489","DOIUrl":"10.1016/j.retram.2024.103489","url":null,"abstract":"<div><div>The traditional method of CAR T cell production involves lengthy <em>ex-vivo</em> culture times which can result in the reduction of crucial naïve T cell subsets. Moreover, traditional CAR T cell therapy manufacturing processes can prolong time-to-patient, potentially delaying patient treatment, and contribute to disease progression. In this study, we describe an innovative and semi-automated 24-hour CAR T manufacturing process that yields a higher percentage of naïve/stem-cell like T cells which showed high cytotoxic activity and cytokine release in vitro. The data supports the feasibility of implementing this streamlined manufacturing process in clinics. This approach also has the potential to enhance CAR T therapy efficacy and improve patient access to therapy.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103489"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2024.103488
Zixuan Wang , Guangji Zhang
In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer immunotherapy. Particularly in hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL), B cell lymphomas and multiple myeloma. CAR-T therapy has demonstrated remarkable clinical efficacy, leading to the approval of several CAR-T cell products and offering significant benefits to numerous leukemia patients. Despite these successes, the application of CAR-T cells in solid tumors remains limited due to significant challenges, including immunosuppressive tumor microenvironments, heterogeneous antigen expression, and treatment-associated toxicities. In parallel with CAR-T development, researchers are investigating other immune cell platforms to overcome these obstacles. Among these, invariant natural killer T (iNKT) cells have garnered increasing attention for their unique immunological properties. Unlike conventional T cells, iNKT cells are a subset of T lymphocytes characterized by the expression of a semi-invariant T-cell receptor (TCR) that recognizes lipid antigens presented by CD1d molecules. This distinctive antigen recognition mechanism enables iNKT cells to bridge innate and adaptive immunity, granting them potent antitumor activity and the ability to modulate the tumor microenvironment. Additionally, iNKT cells exhibit intrinsic resistance to exhaustion and an enhanced ability to infiltrate solid tumors compared to traditional T cells. Building on these properties, researchers are leveraging CAR technology to enhance iNKT cell tumor-targeting capabilities, aiming to overcome barriers encountered in solid tumor therapy. This review provides an in-depth discussion of the application and therapeutic potential of CAR-iNKT cells in cancer immunotherapy, with a focus on their advantages over conventional CAR-T cells and their role in addressing the challenges of solid tumor treatment.
{"title":"CAR-iNKT cell therapy: mechanisms, advantages, and challenges","authors":"Zixuan Wang , Guangji Zhang","doi":"10.1016/j.retram.2024.103488","DOIUrl":"10.1016/j.retram.2024.103488","url":null,"abstract":"<div><div>In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer immunotherapy. Particularly in hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL), B cell lymphomas and multiple myeloma. CAR-T therapy has demonstrated remarkable clinical efficacy, leading to the approval of several CAR-T cell products and offering significant benefits to numerous leukemia patients. Despite these successes, the application of CAR-T cells in solid tumors remains limited due to significant challenges, including immunosuppressive tumor microenvironments, heterogeneous antigen expression, and treatment-associated toxicities. In parallel with CAR-T development, researchers are investigating other immune cell platforms to overcome these obstacles. Among these, invariant natural killer T (iNKT) cells have garnered increasing attention for their unique immunological properties. Unlike conventional T cells, iNKT cells are a subset of T lymphocytes characterized by the expression of a semi-invariant T-cell receptor (TCR) that recognizes lipid antigens presented by CD1d molecules. This distinctive antigen recognition mechanism enables iNKT cells to bridge innate and adaptive immunity, granting them potent antitumor activity and the ability to modulate the tumor microenvironment. Additionally, iNKT cells exhibit intrinsic resistance to exhaustion and an enhanced ability to infiltrate solid tumors compared to traditional T cells. Building on these properties, researchers are leveraging CAR technology to enhance iNKT cell tumor-targeting capabilities, aiming to overcome barriers encountered in solid tumor therapy. This review provides an in-depth discussion of the application and therapeutic potential of CAR-iNKT cells in cancer immunotherapy, with a focus on their advantages over conventional CAR-T cells and their role in addressing the challenges of solid tumor treatment.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103488"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2024.103490
Yoshiyasu Takefuji
{"title":"Unraveling misinterpretations in pediatric COVID-19 admission trends: The Impact of CDC Reporting Changes","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.retram.2024.103490","DOIUrl":"10.1016/j.retram.2024.103490","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103490"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.retram.2025.103507
{"title":"Thanks to reviewers","authors":"","doi":"10.1016/j.retram.2025.103507","DOIUrl":"10.1016/j.retram.2025.103507","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103507"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-10-29DOI: 10.1016/j.retram.2024.103476
Giorgia Battipaglia, Nicola Polverelli, Joe Tuffnell, Patrizia Chiusolo, Marie Robin, Massimiliano Gambella, Annoek Broers, Elisa Sala, Jakob Passweg, Sabine Furst, Lone Smidtrup Friis, Remy Dulery, Moniek de Witte, Micha Srour, Maria Chiara Finazzi, Claudia Wehr, Arnon Nagler, Deborah Richardson, Wolfgang Bethge, Andrew Clark, Joanna Drozd-Sokolowska, Kavita Raj, Tomasz Czerw, Juan Carlos Hernández-Boluda, Donal P McLornan
Heterogeneous approaches exist in regard to the management of disease-related co-morbidities in potential allogeneic haematopoietic cell transplantation (allo-HCT) candidates with myelofibrosis (MF). The EBMT Chronic Malignancies Working Party launched an electronic survey to evaluate how MF-specific comorbidities are approached and whether they ultimately affect the decision to transplant. A total of 41/63 (65%) Centers, all of whom were experienced in the management of MF allo-HCT, responded. Responses were aggregated and reported in a comparative fashion. Screening for portal hypertension (PH) was routinely performed in 54% centers, never in 12% and guided by clinical manifestations in the remaining. Involvement of hepatologists/gastroenterologists was always/very often considered in patients with signs of PH prior to transplant. Centers reported that radiological evidence of PH did not routinely represent a formal contraindication for allo-HCT in most cases (78%). Of note, most centers (61%) did not perform routine screening for gastroesophageal varices; this was systematically considered or guided by clinical manifestations in only 7% and 32% centers, respectively. Presence of gastroesophageal varices was always (15%) or occasionally (19%) considered a formal contraindication to allo-HCT. A prior history of portal vein thrombosis never (78%) or occasionally (15%) represented a formal contraindication. Three Centers would not proceed to transplant in such cases. Less importance was assigned to non-portal splanchnic vein thrombosis (SVT), with all but one centre proceeding to transplant regardless of prior SVT. This survey highlights a considerable heterogeneity across responding centers in approaching MF-related comorbidities prior to transplant, suggesting that harmonisation guidelines are needed to address these issues in this patient population.
{"title":"Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT.","authors":"Giorgia Battipaglia, Nicola Polverelli, Joe Tuffnell, Patrizia Chiusolo, Marie Robin, Massimiliano Gambella, Annoek Broers, Elisa Sala, Jakob Passweg, Sabine Furst, Lone Smidtrup Friis, Remy Dulery, Moniek de Witte, Micha Srour, Maria Chiara Finazzi, Claudia Wehr, Arnon Nagler, Deborah Richardson, Wolfgang Bethge, Andrew Clark, Joanna Drozd-Sokolowska, Kavita Raj, Tomasz Czerw, Juan Carlos Hernández-Boluda, Donal P McLornan","doi":"10.1016/j.retram.2024.103476","DOIUrl":"10.1016/j.retram.2024.103476","url":null,"abstract":"<p><p>Heterogeneous approaches exist in regard to the management of disease-related co-morbidities in potential allogeneic haematopoietic cell transplantation (allo-HCT) candidates with myelofibrosis (MF). The EBMT Chronic Malignancies Working Party launched an electronic survey to evaluate how MF-specific comorbidities are approached and whether they ultimately affect the decision to transplant. A total of 41/63 (65%) Centers, all of whom were experienced in the management of MF allo-HCT, responded. Responses were aggregated and reported in a comparative fashion. Screening for portal hypertension (PH) was routinely performed in 54% centers, never in 12% and guided by clinical manifestations in the remaining. Involvement of hepatologists/gastroenterologists was always/very often considered in patients with signs of PH prior to transplant. Centers reported that radiological evidence of PH did not routinely represent a formal contraindication for allo-HCT in most cases (78%). Of note, most centers (61%) did not perform routine screening for gastroesophageal varices; this was systematically considered or guided by clinical manifestations in only 7% and 32% centers, respectively. Presence of gastroesophageal varices was always (15%) or occasionally (19%) considered a formal contraindication to allo-HCT. A prior history of portal vein thrombosis never (78%) or occasionally (15%) represented a formal contraindication. Three Centers would not proceed to transplant in such cases. Less importance was assigned to non-portal splanchnic vein thrombosis (SVT), with all but one centre proceeding to transplant regardless of prior SVT. This survey highlights a considerable heterogeneity across responding centers in approaching MF-related comorbidities prior to transplant, suggesting that harmonisation guidelines are needed to address these issues in this patient population.</p>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"103476"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-31DOI: 10.1016/j.retram.2024.103491
Wenwen Chen, Luxia Xu, Zhigang Guo, Muya Zhou
Cancer remains one of the most pressing health challenges worldwide. Recently, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising approach for treating hematological cancers. However, the translation of CAR-T cell therapy to solid tumors faces formidable obstacles, notably the immunosuppressive tumor microenvironment. Within solid tumors, CAR-T cells encounter a hostile milieu that promotes exhaustion and diminishes their long-term effectiveness against cancer cells. Optimizing the manufacturing process is paramount to ensuring the efficacy of CAR-T cell therapy in solid tumors. A critical aspect of this optimization lies in refining the composition of cell culture media. By supplementing basic culture media with specific additives, researchers aim to improve the behavior and functionality of CAR-T cells, thereby enhancing their therapeutic potential. This review delves into the culture media additives that have been investigated or show promise in modulating CAR-T cell phenotypes and enhancing their anti-tumor efficacy. We explore various types of additives and their mechanisms of action to mitigate exhaustion and augment persistence within the challenging solid tumor microenvironment. By shedding light on the latest advancements in culture media optimization for CAR-T cell therapy, this review aims to provide insights into novel strategies for overcoming the hurdles posed by solid tumors. Ultimately, these insights hold the potential to enhance the effectiveness of CAR-T cell therapy and improve outcomes for cancer patients.
{"title":"Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives","authors":"Wenwen Chen, Luxia Xu, Zhigang Guo, Muya Zhou","doi":"10.1016/j.retram.2024.103491","DOIUrl":"10.1016/j.retram.2024.103491","url":null,"abstract":"<div><div>Cancer remains one of the most pressing health challenges worldwide. Recently, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising approach for treating hematological cancers. However, the translation of CAR-T cell therapy to solid tumors faces formidable obstacles, notably the immunosuppressive tumor microenvironment. Within solid tumors, CAR-T cells encounter a hostile milieu that promotes exhaustion and diminishes their long-term effectiveness against cancer cells. Optimizing the manufacturing process is paramount to ensuring the efficacy of CAR-T cell therapy in solid tumors. A critical aspect of this optimization lies in refining the composition of cell culture media. By supplementing basic culture media with specific additives, researchers aim to improve the behavior and functionality of CAR-T cells, thereby enhancing their therapeutic potential. This review delves into the culture media additives that have been investigated or show promise in modulating CAR-T cell phenotypes and enhancing their anti-tumor efficacy. We explore various types of additives and their mechanisms of action to mitigate exhaustion and augment persistence within the challenging solid tumor microenvironment. By shedding light on the latest advancements in culture media optimization for CAR-T cell therapy, this review aims to provide insights into novel strategies for overcoming the hurdles posed by solid tumors. Ultimately, these insights hold the potential to enhance the effectiveness of CAR-T cell therapy and improve outcomes for cancer patients.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 2","pages":"Article 103491"},"PeriodicalIF":3.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号